Comparing 0 vendors in Spatial Genomics and Transcriptomics across 0 criteria.
Contenders
Emerging Companies
Become a Client
- Access Exclusive Reports, expert insights and tailored support to drive growth.
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
2.1 DRIVERS
2.1.1 Increasing adoption of spatial genomics & transcriptomics in drug discovery &
development
2.1.2 Introduction of novel products
2.1.3 Increasing R&D investments and public-private funding
2.2 RESTRAINTS
2.2.1 High capital investments
2.3 OPPORTUNITIES
2.3.1 Increasing use of spatial omics for biomarker identification
2.4 CHALLENGES
2.4.1 Dearth of skilled professionals
3.1 INTRODUCTION
3.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS
3.3 REVENUE SHARE ANALYSIS (TOP SIX PLAYERS)
3.4 MARKET SHARE ANALYSIS (2021)
3.5 COMPANY EVALUATION QUADRANT
3.5.1 STARS
3.5.2 EMERGING LEADERS
3.5.3 PERVASIVE PLAYERS
3.5.4 PARTICIPANTS
4.1 KEY PLAYERS
4.1.1 NANOSTRING TECHNOLOGIES
TABLE 248 NANOSTRING TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 31 NANOSTRING TECHNOLOGIES: COMPANY SNAPSHOT (2021)
4.1.2 10X GENOMICS
TABLE 249 10X GENOMICS: BUSINESS OVERVIEW
FIGURE 32 10X GENOMICS: COMPANY SNAPSHOT (2021)
4.1.3 ILLUMINA
TABLE 250 ILLUMINA: BUSINESS OVERVIEW
FIGURE 33 ILLUMINA: COMPANY SNAPSHOT (2021)
4.1.4 BIO-RAD LABORATORIES
TABLE 251 BIO-RAD: BUSINESS OVERVIEW
FIGURE 34 BIO-RAD: COMPANY SNAPSHOT (2021)
4.1.5 BIO-TECHNE
TABLE 252 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 35 BIO-TECHNE: COMPANY SNAPSHOT (2021)
4.1.6 STANDARD BIOTOOLS
TABLE 253 STANDARD BIOTOOLS: BUSINESS OVERVIEW
FIGURE 36 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2021)
4.1.7 GENOMIC VISION SA
TABLE 254 GENOMIC VISION: BUSINESS OVERVIEW
FIGURE 37 GENOMIC VISION: COMPANY SNAPSHOT (2021)
4.1.8 AKOYA BIOSCIENCES
TABLE 255 AKOYA BIOSCIENCES: BUSINESS OVERVIEW
FIGURE 38 AKOYA BIOSCIENCES: COMPANY SNAPSHOT (2021)
4.1.9 PERKINELMER
TABLE 258 PERKINELMER: BUSINESS OVERVIEW
FIGURE 41 PERKINELMER: COMPANY SNAPSHOT (2021)
4.1.10 SEVEN BRIDGES GENOMICS
TABLE 259 SEVEN BRIDGES GENOMICS: BUSINESS OVERVIEW
4.1.11 S2 GENOMICS
TABLE 260 S2 GENOMICS: BUSINESS OVERVIEW
4.1.12 CANTATA BIO
TABLE 261 CANTATA BIO: BUSINESS OVERVIEW
4.1.13 VIZGEN CORP
TABLE 262 VIZGEN: BUSINESS OVERVIEW
4.2 OTHER PLAYERS
4.2.1 BIOSPYDER TECHNOLOGIES
4.2.2 OPTICAL BIOSYSTEMS
4.2.3 MILTENYL BIOTEC
4.2.4 RARECYTE
4.2.5 ULTIVUE
4.2.6 LUNAPHORE TECHNOLOGIES
4.2.9 SINGULAR GENOMICS
4.2.10 VERACYTE
The Spatial Genomics & Transcriptomics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Spatial Genomics & Transcriptomics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 40 companies of which the Top xx Spatial Genomics & Transcriptomics Companies were categorized and recognized as the quadrant leaders.
The growth of the market is primarily driven by the transition from purely research-focused applications to drug discovery and development, particularly in areas like neurodegenerative diseases and cancer. Spatial genomics and transcriptomics are expected to play a significant role in addressing unmet clinical needs in oncology, including the growing demand for predictive biomarkers of treatment response. These biomarkers enhance the development of immunotherapies by providing deeper insights into tumor biology. However, the market's expansion is hindered by uncertainties surrounding the outcomes of transcriptomic research and the high costs associated with advanced equipment, which have slowed the adoption of transcriptomic technologies.
Genomics and transcriptomics play a crucial role in accelerating drug discovery and development. Spatial techniques are increasingly employed to deepen our understanding of infectious diseases. Over time, the applications of spatial genomics and transcriptomics have broadened, focusing on generating valuable insights into neurodegenerative diseases and cancer. In oncology, these approaches are expected to address a significant unmet clinical need: the identification of predictive biomarkers of response. Such biomarkers are instrumental in advancing immunotherapy development by providing a more comprehensive understanding of the tumor microenvironment.The 360 Quadrant maps the Spatial Genomics & Transcriptomics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Spatial Genomics & Transcriptomics quadrant. The top criteria for product footprint evaluation included Technique (Spatial Transcriptomics and Spatial Genomics), Product (Instruments, Consumables and Software) Application (Translational Research, Drug Discovery) and End-User.Key Players:
Some of the prominent players are NanoString Technologies, Inc. (US), 10X Genomics (US), Illumina (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), Standard BioTools Inc. (US), Genomic Vision SA (France), Akoya Biosciences, Inc. (US), Danaher Corporation (US), Natera, Inc. (US), PerkinElmer, Inc. (US), Seven Bridges Genomics (US), S2 Genomics, Inc. (US), Cantata Bio (US), Vizgen Corporation (US), BioSpyder Technologies Inc. (US), Optical Biosystems Inc. (US), Miltenyi Biotec (Germany), Ultivue Inc. (US), Lunaphore Technologies SA (Switzerland), Rebus Biosystems LLC (US), Resolve Biosciences (Germany), Singular Genomics, Inc. (US), and Veracyte (US).Spatial genomics and transcriptomics are advanced techniques that combine spatial information with genomic or transcriptomic data. These methods allow scientists to analyze the spatial arrangement of cells and their gene expression patterns within tissues, providing insights into the complex organization and function of biological systems.
These techniques involve capturing spatial information about cells within a tissue sample using imaging or sequencing technologies. Spatially resolved data is then combined with genomic or transcriptomic analysis to map gene expression patterns to specific locations within the tissue.
- Cancer research: Understanding tumor microenvironments and identifying predictive biomarkers for immunotherapy.
- Infectious diseases: Studying pathogen-host interactions and immune responses.
- Neurodegenerative diseases: Mapping neuronal circuits and studying disease progression.
- Developmental biology: Understanding tissue development and cellular differentiation.
- Drug discovery: Identifying new therapeutic targets and evaluating treatment effects.
- High cost and complexity of techniques.
- Limited availability of standardized protocols.
- Handling large datasets and integrating spatial and molecular data.
- Need for advanced computational tools for analysis.
In oncology, these techniques are pivotal in exploring tumor heterogeneity, identifying predictive biomarkers of response, and developing more effective immunotherapies by offering insights into the tumor microenvironment.
Academic research institutions, pharmaceutical companies, and biotechnology firms are key players adopting spatial genomics and transcriptomics to accelerate discoveries in disease biology and drug development.
Computational tools are essential for processing, visualizing, and analyzing the vast datasets generated. They enable the integration of spatial and transcriptomic data and help derive meaningful biological insights.
The Full List
